Ceftibuten

Ceftibuten

Systematic (IUPAC) name
(6R,7R)-7-([(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino) -8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names	Cedax
AHFS/Drugs.com	monograph
MedlinePlus	a698023
Legal status	?
Identifiers
CAS number	97519-39-6 Y
ATC code	J01DD14
PubChem	CID 5282242
DrugBank	DB01415
ChemSpider	4445419 Y
UNII	IW71N46B4Y Y
KEGG	D00922 Y
ChEBI	CHEBI:3510 Y
ChEMBL	CHEMBL1605 Y
Chemical data
Formula	C15H14N4O6S2
Mol. mass	410.427 g.mol-1
SMILES O=C2N1/C(=C\CS[C@@H]1[C@@H]2NC(=O)C(=C/CC(=O)O)\c3nc(sc3)N)C(=O)O
InChI InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1 Y Key:UNJFKXSSGBWRBZ-BJCIPQKHSA-N Y
Y (what is this?)  (verify)

Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent, with 2 dosage forms, capsule or oral suspension. It is marketed by Pernix Therapeutics under the trade name Cedax.

It is active against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli (K. pneumoniae, K. oxytoca), Proteus vulgaris, P. mirabils, P. providence, Salmonella sp., Shigella sp., Enterobacter sp. and Streptococcus sp.

Clinical use

Indications

Ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. It is also indicated for pneumonia, infections of the urinary tract, enteritis and gastroenteritis.^{[citation needed]}

Adverse reactions

In studies made in 3,000 patients ceftibuten was well tolerated. Most frequent reactions were gastrointestinal and nauseas.

Formulations

Ceftibuten is available as capsules containing 400 mg, and a powder for oral suspension containing 180 mg per 5 ml.

External links

• Manufacturer's website
• Drug information from RxList